clinic
virolog
best
kept
secret
molecular
virolog
workshop
clinic
virolog
symposium
cv
held
clearwat
beach
florida
spring
secret
annual
cv
april
attend
clinic
virologist
interest
individu
attend
workshop
april
meet
organ
pan
american
societi
clinic
virolog
pascv
univers
south
florida
colleg
medicin
gather
character
high
qualiti
focu
present
live
question
answer
session
least
meet
locat
modest
older
hotel
beauti
gulf
mexico
beach
increas
popular
meant
year
first
time
shuttl
buse
hire
bring
attende
nearbi
hotel
frederick
nolt
fn
phd
emori
univers
school
medicin
atlanta
ga
spoke
creat
molecular
diagnost
laboratori
cover
everi
aspect
space
workflow
staf
instrument
cost
reimburs
regulatori
issu
within
last
year
molecular
diagnost
laboratori
emori
experienc
growth
test
volum
test
almost
test
increas
demand
new
marker
avail
open
analyt
system
motiv
laboratori
develop
inhous
assay
sinc
diagnost
industri
kept
pace
human
papilloma
viru
hpv
dna
test
implement
disast
cytolog
depart
chose
method
would
use
predict
would
refer
specimensyear
actual
refer
samplesyear
first
year
lab
cost
base
biweekli
batch
medicar
reimburs
turn
around
time
long
year
gave
start
send
test
peopl
indic
question
period
believ
hpv
dna
replac
pap
papanicoleau
smear
stain
eventu
screen
cervic
cancer
test
bk
viru
bkv
dna
renal
transplant
patient
allograft
failur
big
success
provid
good
servic
get
reimburs
process
organ
everyon
provid
care
end
stage
renal
diseas
esrd
talk
bkv
also
got
everyon
talk
multipl
issu
result
improv
diagnosi
manag
nephropathi
author
hurt
esrd
essenti
cart
blanch
reimburs
us
discuss
period
sampl
choic
bkv
blood
plenti
signal
urin
contamin
problem
clinic
signific
lack
transplant
patient
viru
urin
viremia
develop
nephropathi
fn
ask
share
knowledg
primer
probe
offer
share
slide
enteroviru
suggest
demand
test
especi
summer
time
realtim
pcr
method
provid
precis
quantit
result
tradit
pcr
accord
one
comment
unidirect
workflow
still
indic
longer
strictli
necessari
isol
preand
postamplif
activ
closedtub
realtim
pcr
method
exclus
use
justifi
cost
look
cost
reagent
labor
bring
servic
shorten
length
stay
otherwis
save
hospit
cost
qc
need
lot
chang
master
mix
extract
reagent
fn
lab
run
everi
test
daili
six
day
week
think
seven
one
question
brought
idea
use
singl
intern
control
like
dolphin
hsv
test
set
mani
lab
probabl
area
clinic
diagnost
use
inhous
method
next
three
talk
focus
design
valid
regul
method
david
r
hillyard
md
dh
arup
laboratori
salt
lake
citi
ut
spoke
select
design
primer
probe
somewhat
surpris
suggest
nt
least
scratch
mani
problem
target
select
lack
data
show
taxonom
relat
polyphorm
sequenc
design
singl
nucleotid
polymorph
snp
limit
publish
sequenc
data
avail
trip
inexperienc
investig
approach
advis
order
multipl
primer
set
use
publish
assay
take
advantag
exist
technic
clinic
valid
even
assum
design
work
discuss
follow
one
spoke
de
novo
design
primer
probe
sever
peopl
describ
problem
aros
new
inhous
test
prime
failur
due
inaccur
melt
temperatur
calcul
primer
dimer
hairpin
selfcomplementar
format
nonspecif
prime
amplicon
summari
dh
consid
snp
difficult
detect
sequenc
sequenc
data
base
inadequ
identifi
relev
snp
primer
probe
alexandra
valsamaki
md
av
john
hopkin
hospit
health
system
baltimor
md
describ
approach
validationverif
homebrew
molecular
assay
adapt
protocol
variou
publish
guidelin
nccl
colleg
american
pathologist
cap
evalu
accuraci
reproduc
sensit
specif
limit
detect
refer
report
rang
qualit
quantit
test
continu
postverif
process
month
implement
need
data
evalu
gap
fill
mandatori
inclus
extern
control
standard
variou
commerci
avail
sourc
eg
standard
hepat
b
c
viru
human
immunodefici
viru
hiv
parvoviru
recommend
statist
lod
limit
detect
could
done
probit
analysi
still
yet
unidentifi
inhibitor
polymeras
chain
reaction
pcr
addit
known
inhibitor
methanol
heparin
sd
glycerol
variou
polysaccharid
av
promot
pragmat
care
organ
key
factor
consist
use
valid
effort
warn
win
battl
lose
war
analytespecif
reagent
asr
issu
challeng
topic
address
salli
hojvat
phd
us
food
drug
administr
rockvil
md
asr
defin
fda
regul
antibodi
polyclon
monoclon
receptor
protein
ligand
nucleic
acid
sequenc
similar
reagent
specif
bind
chemic
reaction
substanc
specimen
intend
use
diagnost
applic
identif
quantif
individu
chemic
substanc
ligand
biolog
specimen
cfr
describ
fda
intent
promulg
asr
rule
bring
activ
ingredi
variou
inhous
method
regul
would
improv
oversight
test
asr
rule
manufactur
respons
registr
list
reagent
manufactur
use
qualiti
system
regul
qsr
postmarket
report
seriou
advers
event
label
accord
fda
requir
disclaim
clinic
perform
claim
instruct
use
intend
use
asr
may
sold
high
complex
laboratori
laboratori
respons
function
high
complex
lab
clia
regul
establish
perform
test
use
asr
assembl
laboratori
label
result
specif
disclaim
test
develop
perform
characterist
determin
laboratori
name
clear
approv
fda
challeng
rule
includ
difficulti
fda
asr
databas
creativ
compani
market
devic
asr
close
resembl
test
kit
ruo
research
use
iuo
investig
use
diagnost
addit
asr
diagnost
need
differenti
fdaclear
diagnost
go
forward
fda
continu
consid
asr
rule
better
appli
encourag
new
ivd
technolog
diminish
concern
safeti
effect
ensur
qualiti
diseas
control
prevent
publish
case
definit
sar
serolog
use
case
definit
epidemiolog
either
viru
cultur
slow
insensit
requir
level
three
laboratori
better
rtpcr
revers
transcriptas
pcr
nasopharyng
swab
throat
swab
stool
sputum
bronchoscopi
specimen
use
surprisingli
stool
prove
best
specimen
sinc
posit
earli
day
clinic
present
still
later
posit
high
titer
summari
laboratori
choic
select
sar
test
either
convent
serolog
real
time
inhous
commerci
avail
rtpcr
assay
base
need
avail
instrument
four
commerci
avail
sarscov
test
market
provid
artu
biotech
roch
prodess
eragen
bioscienc
three
excel
analyt
sensit
use
purifi
rna
poor
clinic
sensit
singl
specimen
thu
jm
recommend
includ
test
multipl
specimen
sarscov
rna
respiratori
plu
stool
plu
follow
specimen
use
second
amplif
target
confirmatori
test
improv
pcr
assay
requir
detect
case
time
fashion
also
improv
sensit
specif
antibodi
test
requir
earlier
diagnosi
initi
test
rtpcr
posit
toronto
patient
mean
day
onset
collect
convalesc
serolog
posit
mean
time
day
rtpcr
often
posit
specimen
collect
day
diseas
hmpv
member
paramyxovirida
famili
classifi
genu
metapneumoviru
subfamili
pneumovirina
first
isol
netherland
infect
usual
occur
winter
month
common
children
infect
often
affect
lower
respiratori
tract
similar
rsv
respiratori
syncyti
viru
diagnosi
hmpv
done
cell
cytopath
effect
observ
focal
round
convent
real
time
pcr
assay
target
differ
gene
nucleocapsid
fusion
gene
primer
amplifi
bp
fragment
suggest
forward
revers
amplifi
bp
fragment
summari
sarscov
hmpv
diagnosi
requir
multipl
specimen
multipl
site
multipl
techniqu
infect
known
depend
immun
statu
patient
ebv
seem
success
viru
sinc
elderli
infect
quantit
assay
ebv
viral
load
qebv
requir
diagnos
sever
infect
qebv
may
use
predict
risk
ebv
diseas
posttranspl
patient
monitor
diseas
progress
monitor
effect
intervent
diagnos
primari
ebv
infect
especi
children
hb
present
data
seri
acut
infecti
mononucleosi
trial
among
univers
minnesota
student
one
trial
includ
student
primari
infecti
mononucleosi
defin
follow
serolog
basi
viral
capsid
antigen
vca
igm
posit
vcaigg
neg
epsteinbarr
nuclear
antigen
igg
neg
author
wonder
also
posit
vcaigg
sinc
isol
vcaigm
common
marker
ebvacut
phase
sera
et
al
hess
subject
median
sever
ill
score
scale
day
clinic
present
coincid
highest
median
concentr
ebv
whole
blood
copiesml
peripher
blood
monocyt
pbmc
copiesml
ebv
commonli
found
plasma
plasma
sampl
test
contain
detect
viru
viral
decay
pbmc
parallel
whole
blood
median
decay
halflif
day
highest
concentr
ebv
site
sampl
oral
wash
week
onset
ill
median
copiesml
five
subject
follow
visit
one
year
acut
ill
one
still
detect
viru
either
oral
pellet
supernat
fluid
summari
young
adult
primari
infecti
mononucleosi
copi
ebv
oral
wash
blood
pbmc
patient
past
ebv
infect
hb
comment
two
addit
studi
qebv
oral
wash
attempt
pinpoint
oral
shed
begin
declin
exactli
vca
igg
antibodi
develop
eight
student
confirm
infecti
mononucleosi
data
still
pend
author
evidenc
discuss
follow
far
clear
specimen
use
viral
load
whether
cellfre
specimen
plasma
serum
leucocyt
also
current
know
viral
load
distinguish
infect
diseas
whether
qebv
use
monitor
antiebv
therapi
whether
immun
respons
data
combin
viral
load
predict
clinic
outcom
william
carman
phd
west
scotland
specialist
virolog
centr
glasgow
scotland
spoke
molecular
diagnosi
respiratori
virus
necessari
current
respiratori
virus
influenza
b
rsv
parainfluenza
metapneumovirus
adenovirus
enterovirus
rhinovirus
other
diagnos
either
direct
immunofluoresc
dif
electron
microscopi
em
cultur
serolog
compar
result
viru
cultur
nucleic
acid
test
nat
nat
realtim
pcr
provid
better
sensit
clear
advantag
test
eg
rhinoviru
cultur
versu
nat
metapneumoviru
cultur
versu
nat
sarscov
cultur
versu
nat
coronavirus
cultur
versu
approxim
nat
cultur
usual
take
sever
day
complet
nat
done
within
day
posit
predict
valu
ppv
nat
may
ppv
cultur
compar
cost
test
includ
work
load
dif
cultur
pcr
thu
futur
respiratori
diagnosi
suggest
end
cultur
larg
refer
lab
increas
knowledg
base
clinic
implic
improv
strategi
adequ
epidemiolog
potenti
quantit
viral
load
narrow
usag
divers
primerprob
commerci
test
method
lower
cost
increas
competit
vignett
good
correl
pleocytosi
ev
pcr
csf
eg
patient
month
age
pleocytosi
patient
neg
ev
rtpcr
neg
predict
valu
vignett
major
issu
cmv
genotyp
might
detect
resist
gancyclovir
gcv
either
cultur
plaqu
assay
pcrren
restrict
enzym
assay
sequenc
studi
gcvresist
virus
mutat
dna
polymeras
gene
thu
one
must
use
plaqu
reduct
assay
sequenc
gene
also
detect
mutat
confer
cidovir
foscarnet
resist
vignett
earli
three
nest
set
primer
pol
gag
env
develop
detect
hiv
provir
dna
specimen
test
pol
primer
set
neg
report
posit
confirm
either
gag
env
reoptim
primer
avail
eg
stratagen
optiprim
tm
kit
provid
huge
improv
gel
readout
vignett
rsv
infect
season
winter
time
b
pertussi
infect
mainli
occur
summer
thu
recommend
test
bordetella
pertussi
winter
respiratori
season
basi
epidemiolog
data
present
vignett
lab
test
skin
mucou
membran
lesion
hsv
pcr
specimen
test
specimen
vzv
thirtyeight
percent
sampl
posit
hsv
neg
fortyf
percent
sampl
posit
vzv
neg
retrospect
studi
determin
often
vzv
dna
present
lesion
specimen
hsv
pcr
order
skin
mucou
membran
lesion
due
hsv
vzv
look
similar
result
none
mucou
membran
specimen
neg
hsv
pcr
either
genit
oral
vzv
pcr
posit
genit
specimen
oral
specimen
vzv
dna
detect
dermal
specimen
vzv
pcr
request
hsv
pcr
neg
specimen
conclud
dermal
lesion
specimen
submit
hsv
pcr
consid
vzv
test
sinc
hsv
vzv
difficult
distinguish
visual
